Dupixent Set To Dominate Bullous Pemphigoid Space
Argenx has discontinued Vyvgart for the rare skin disease as other potential candidates linger in the very early stages of development.
Argenx has discontinued Vyvgart for the rare skin disease as other potential candidates linger in the very early stages of development.